Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Compounding Enforcement Continues With Teregen Labs Citation

This article was originally published in The Pink Sheet Daily

Executive Summary

The Gentere subsidiary distributes compounded drug products for those commercially available and without valid prescriptions, an FDA warning letter states. The agency also cites the firm for cGMP violations.

You may also be interested in...



FDA Cites Respi Care As Part Of Pharmacy Compounding Enforcement

The agency issues its second “warning letter” in a month citing a pharmacy’s compounding operations as comparable to that of a drug manufacturer. The agency also notes cGMP violations observed during an inspection of Respi Care’s facility in Puerto Rico.

FDA Cites Respi Care As Part Of Pharmacy Compounding Enforcement

The agency issues its second “warning letter” in a month citing a pharmacy’s compounding operations as comparable to that of a drug manufacturer. The agency also notes cGMP violations observed during an inspection of Respi Care’s facility in Puerto Rico.

Pharmacy's Compounding Resembles Rx Manufacturing Operation, FDA Says

FDA "warning letter" states that Lincare and Reliant Pharmacy produce "essentially copies of commercially available drugs" without documented patient-specific medical need. This practice goes beyond the scope of traditional compounding, the letter states.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel